SCHEMBL10313535

SCHEMBL10313535

Cc1ccc(-c2c(C)nn3c(=O)cc(-c4ccc(F)cc4F)n(C)c23)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.39
NR3C2 P08235 1/20 0.39
MAPT P10636 5/20 0.37
THRB P10828 2/20 0.37
AR P10275 1/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
NPC1 O15118 1/20 0.34
LMNA P02545 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
RAD51 Q06609 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ADORA2A P29274 1/20 0.34
ADORA2B P29275 1/20 0.34
ADORA1 P30542 1/20 0.34
OPRM1 P35372 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
KIT P10721 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10275666 0.89 MAPT (0.38) PGRNR3C2MAPTTHRBNPC1
SCHEMBL10282694 0.83 HSD11B1 (0.45) THRB
SCHEMBL10313536 0.81 PGR (0.42) PGRNR3C2MAPTTHRBAR
SCHEMBL10275202 0.81 MAPT (0.39) PGRNR3C2MAPTARMEN1
SCHEMBL10275378 0.81 NPC1 (0.38) PGRNR3C2MAPTTHRBNPC1
SCHEMBL10275392 0.80 MAPT (0.36) PGRNR3C2MAPTTHRBLMNA
SCHEMBL10275521 0.80 AR (0.36) PGRNR3C2ARKDM4EALDH1A1
SCHEMBL10313510 0.77 RAD51 (0.45) MAPTNPC1RAB9ASMN1; SMN2RAD51
SCHEMBL10276069 0.77 MAPT (0.49) MAPTNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL10313520 0.76 RAD51 (0.44) LMNARAD51KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF XU LIFENG (US) 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178915-A1 PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF TYMP, TYMS, ADORA3 PGR 3472/4885NR3C2 1731/4885MAPT 750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.